Ki-67 biomarker in breast cancer of Indian women

North American Journal of Medical Sciences

Volumn 3, Issue 3, 2011, Pages 119-128

  Patil, Amit V ^a   Singhai, Rajeev ^b   Bhamre, Rahul S ^c   Patil, Vinayak W ^b  

^a Government Medical College   (India)

^b SIR J J GROUP OF HOSPITALS   (India)

^c Dr DY Patil Hospital and Research Centre   (India)

Author keywords

Apoptotic index; Breast cancer; Chemotherapy; Ki 67 (MIB 1); Primary systemic therapy; Prognostic factor; Proliferative labeling index

Indexed keywords

CYCLOPHOSPHAMIDE; EPIRUBICIN; FLUOROURACIL; KI 67 ANTIGEN; TAMOXIFEN;

ADJUVANT THERAPY; ADULT; AGED; APOPTOSIS; ARTICLE; BREAST BIOPSY; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER RADIOTHERAPY; CLINICAL ARTICLE; DRUG RESPONSE; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INDIAN; MASTECTOMY; MULTIPLE CYCLE TREATMENT; PARTIAL MASTECTOMY; POSTOPERATIVE CARE; PREDICTION; PROGNOSIS; REPEAT PROCEDURE;

EID: 79953240531     PISSN: None     EISSN: 19472714     Source Type: Journal    
DOI: 10.4297/najms.2011.3119     Document Type: Article

References (55)

1. Makris A, Powles TJ, Ashley SE, et al. A reduction in the requirements for mastectomy in a randomized trial of neoadjuvant chemoendocrine therapy in primary breast cancer. Ann Oncol 1998; 9: 1179-1184.
2. Fisher B, Brown A, Mamounas E, et al. Effect of preoperative chemotherapy on local-regional disease in women with operable breast cancer: findings from National Surgical Adjuvant Breast and Bowel Project B-18. J Clin Oncol 1997; 15: 2483-2493.
3. Fisher B, Bryant J, Wolmark N, et al. Effect of preoperative chemotherapy on the outcome of women with operable breast cancer. J Clin Oncol 1998; 16: 2672-2685.
4. Cleator SJ, Makris A, Ashley SE, et al. Good clinical response of breast cancers to neoadjuvant chemoendocrine therapy is associated with improved overall survival. Ann Oncol 2005; 16: 267-272.
5. Gasparini G, Boracchi P, Verderio P, Bevilacqua P. Cell kinetics in human breast cancer comparison between the prognostic value of the cytofluorimetric S-phase fraction and that of the antibodies to Ki-67 and PCNA antigens detected by immunocytochemistry. Int J Cancer 1994; 57: 822-829.
6. Dawson AE, Norton JA, Weinberg DS. Comparative assessment of proliferation and DNA content in breast carcinoma by image analysis and flow cytometry. Am J Pathol 1990; 136: 1115-1124.
7. Vielh P, Chevillard S, Mosseri V, Donatini B, Magdelenat H. Ki-67 index and S-phase fraction in human breast carcinomas. Comparison and correlations with prognostic factors. Am J Clin Pathol 1990; 94: 681-686.
8. Mainwaring PN, Ellis PA, Detre S, et al. Comparison of in situ methods to assess DNA cleavage in apoptotic cells in patients with breast cancer. J Clin Pathol 1998; 51: 34-37.
9. Hayward JL, Carbone PP, Heuson JC, et al. Assessment of response to therapy in advanced breast cancer: a project of the Programme on Clinical Oncology of the International Union against Cancer, Geneva, Switzerland. Cancer 1977; 39: 1289-1294.
10. Sataloff DM, Mason BA, Prestipino AJ, et al. Pathologic response to induction chemotherapy in locally advanced carcinoma of the breast a determinant of outcome. J Am Coll Surg 1995; 180: 297-306.
11. Akashi-Tanaka S, Tsuda H, Fukuda H, et al. Prognostic value of histopathological therapeutic effects and mitotic index in locally advanced breast cancers after neoadjuvant chemotherapy. Jpn J Clin Oncol 1996; 26: 201-206.
12. Chevallier B, Roche H, Olivier JP, et al. Inflammatory breast cancer. Pilot study of intensive induction chemotherapy (FEC-HD) results in a high histological response rate. Am J Clin Oncol 1993; 16: 223-228.
13. Honkoop AH, Pinedo HM, De Jong JS, et al. Effects of chemotherapy on pathologic and biologic characteristics of locally advanced breast cancer. Am J Clin Pathol 1997; 107:211-218.
14. Kuerer HM, Newman LA, Buzdar AU, et al. Pathologic tumor response in the breast following neoadjuvant chemotherapy predicts axillary lymph node status. Cancer J Sci Am 1998; 4: 230-236.
15. Smith IC, Heys SD Hutcheon AW, et al. Neoadjuvant chemotherapy in breast cancer: significantly enhanced response with docetaxel. J Clin Oncol 2002; 20: 1456-1466.
16. Burcombe RJ, Makris A, Richman PI, et al. Evaluation of ER, PgR, HER-2/neu and Ki-67 as predictors of response to neoadjuvant anthracycline chemotherapy for operable breast cancer. Br J Cancer 2005; 92: 147-155.
17. Brown RW, Allred CD, Clark GM, et al. Prognostic value of Ki-67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res 1996; 2: 585-592.
18. Gaglia P, Bernardi A, Venesio T, et al. Cell proliferation of breast cancer evaluated by anti-BrdU and anti-Ki-67 antibodies: its prognostic value on short-term recurrences. Eur J Cancer 1993; 29A: 1509-1513.
19. Gottardi O, Tabiadon D, Scanzi F, et al. Clinical and prognostic usefulness of Ki67 determination in breast carcinoma. Pathologic 1992; 84: 15-22.
20. Lee AK, Loda M, Mackarem G, et al. Lymph node negative invasive breast carcinoma 1 centimeter or less in size (T1a, bNOMO), clinicopathological features and outcome. Cancer 1997; 79: 761-771.
21. Pierga JY, Leroyer A, Viehl P, et al. Long term prognostic value of growth fraction determination by Ki-67 immunostaining in primary operable breast cancer. Breast Cancer Res Treat 1996; 37: 57-64.
22. Pinder SE, Wencyk P, Sibbering DM, et al. Assessment of the new proliferation marker MIB1 in breast carcinoma using image analysis, associations with other prognostic factors and survival. Br J Cancer 1995; 71: 146-149.
23. Railo M, Lundin J, Haglund C, et al. Ki-67, p53, ER-receptors, ploidy and S-phase as prognostic factors in T1 node negative breast cancer. Acta Oncol 1997; 36: 369-374.
24. Railo M, Nordling S, von Boguslawsky K, et al. Prognostic value of Ki-67 immunolabelling in primary operable breast cancer. Br J Cancer 1993; 68: 579-583.
25. Veronese SM, Gambacorta M. Proliferation index as a prognostic marker in breast cancer. Cancer 1993; 71: 3926-3931.
26. Wintzer HO, Zipfel I, Schulte-Monting J, et al. Ki-67 immunostaining in human breast tumors and its relationship to prognosis. Cancer 1991; 67: 421-428.
27. Archer SG, Eliopoulos A, Spandidos D, et al. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer 1995; 72: 1259-1266.
28. Daidone MG, Luisi A, Martelli G, et al. Biomarkers and outcome after tamoxifen treatment in node-positive breast cancers from elderly women. Br J Cancer 2000; 82: 270-277.
29. Clahsen PC, van de Velde CJ, Duval C, et al. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol 1998; 16: 470-479.
30. Bottini A, Berruti A, Bersiga A, et al. Relationship between tumor shrinkage and reduction in Ki-67 expression after primary chemotherapy in human breast cancer. Br J Cancer 2001; 85: 1106-1112.
31. Clarke RB, Laidlaw IJ, Jones LJ, et al. Effect of tamoxifen on Ki-67 labeling index in human breast tumors and its relationship to estrogen and progesterone receptor status. Br J Cancer 1993; 67: 606-611.
32. MacGrogan G, Mauriac L, Durand M, et al. Primary chemotherapy in breast invasive carcinoma: predictive value of the immunohistochemical detection of hormonal receptors, p53, c-erbB-2, MIB-1, pS2 and GST pi. Br J Cancer 1996; 74: 1458-1465.
33. Rudas M, Gnant MF, Mittlbock M, et al. Thymidine labeling index and Ki-67 growth fraction in breast cancer: comparison and correlation with prognosis. Breast Cancer Res Treat 1994; 32: 165-175.
34. Bottini A, Berruti A, Bersiga A, et al. Effect of neoadjuvant chemotherapy on Ki67 labeling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumors. Anticancer Res 1996; 16: 3105-3110.
35. Ellis PA, Smith IE, Detre S, et al. Reduced apoptosis and proliferation and increased Bcl-2 in residual breast cancer following preoperative chemotherapy. Breast Cancer Res Treat 1998; 48: 107-116.
36. Dardes RD, Horiguchi J, Jordan VC, et al A pilot study of the effects of short-term tamoxifen therapy on Ki-67 labeling index in women with primary breast cancer. Int J Oncol 2000; 16: 25-30.
37. Makris A, Powles TJ, Allred DC, et al. Changes in hormone receptors and proliferation markers in tamoxifen treated breast cancer patients and the relationship with response. Breast Cancer Res Treat 1998; 48: 11-20.
38. Chang J, Powles TJ, Allred DC, et al. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer. J Clin Oncol 1999; 17: 3058-3063.
39. Billgren AM, Rutqvist LE, Tani E, et al. Proliferating fraction during neoadjuvant chemotherapy of primary breast cancer in relation to objective local response and relapse-free survival. Acta Oncol 1999; 38: 597-601.
40. Makris A, Powles TJ, Allred DC, et al. Quantitative changes in cytological molecular markers during primary medical treatment of breast cancer, a pilot study. Breast Cancer Res Treat 1999; 53: 51-59.
41. Honkoop AH, Van Diest PJ, de Jong JS, et al. Prognostic role of clinical, pathological and biological characteristics in patients with locally advanced breast cancer. Br J Cancer 1998; 77: 621-626.
42. Bear HD, Anderson S, Brown A, et al. The effect on tumor response of adding sequential preoperative docetaxel to preoperative doxorubicin and cyclophosphamide: preliminary results from National Surgical Adjuvant Breast and Bowel Project Protocol B-27. J Clin Oncol 2003; 21: 4165-4174.
43. Buchholz TA, Davis DW, McConkey DJ, et al. Chemotherapy-induced apoptosis and Bcl-2 levels correlate with breast cancer response to chemotherapy. Cancer J 2003; 9: 33-41.
44. Symmans WF, Volm M, Shapiro RL, et al. Paclitaxel-induced apoptosis and mitotic arrest assessed by serial fine needle aspiration: implications for early prediction of breast cancer response to neoadjuvant treatment. Clin Cancer Res 2000; 6: 4610-4617.
45. Chang J, Ormerod M, Powles TJ, et al. Apoptosis and proliferation as predictors of chemotherapy response in patients with breast carcinoma. Cancer 2000; 89: 2145-2152.
46. Urruticoechea A, Smith IE, Dowsett M, et al. Proliferation Marker Ki-67 in Early Breast Cancer. J Clin Oncol 2005; 23(28): 7212-7220.
47. Hawkins RA, Tesdale AL, Anderson ED, Levack PA, Chetty U, Forrest AP. Does the estrogen receptor concentration of a breast cancer change during systemic therapy, Br J Cancer 1990; 61: 877-880.
48. Bottini A, Berruti A, Bersiga A, et al. Effect of neoadjuvant chemotherapy on Ki67 labeling index, c-erbB-2 expression and steroid hormone receptor status in human breast tumors. Anticancer Res 1996; 16: 3105-3110.
49. Schneider J, Lucas R, Sanchez J, Ruibal A, Tejerina A, Martin M. Modulation of molecular marker expression by induction chemotherapy in locally advanced breast cancer: correlation with the response to therapy and the expression of MDR1 and LRP. Anticancer Res 2000; 20: 4373-4377.
50. Lo SS, Wang HC, Shyr YM, Lui WY. Can the hormonal receptor status of primary breast cancer be altered by neoadjuvant chemotherapy? J Surg Oncol 1994; 57: 94-96.
51. Jain V, Landry M, Levine EA. The stability of estrogen and progesterone receptors in patients receiving preoperative chemotherapy for locally advanced breast carcinoma. Am Surg 1996; 62: 162-165.
52. Taucher S, Rudas M, Gnant M, et al. Sequential steroid hormone receptor measurements in primary breast cancer with and without intervening primary chemotherapy. Endocr Relat Cancer 2003a; 10: 91-98.
53. McGrogan M, Rosenberg SA, Mule JJ, et al. These clinical findings set the stage for a variety of studies, Why is tumor regression minimal despite the in vivo generation. Clin Cancer Res 2003; 9(8):2973-2980.
54. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumors. Nature 2000; 406: 747-752.
55. Chang JC, Wooten EC, Tsimelzon A, et al. Gene expression profiling for the prediction of therapeutic response to docetaxel in patients with breast cancer. Lancet 2003; 362: 362-369.